NEPH: Nephros, Inc.

IMG_1819

 

Market Cap: $15,158,554

Outstanding Shares: 49,216,086

Float: 13,466,664

 

Notes from the Editor: Nephros, Inc (OTCQB: NEPH) is a medical device company that targets patients with end state renal disease. The company generated $1.9M in revenue in 2015 and has already reported $1.5M in revenue for the first three quarters in 2016. Now that they’ve received FDA clearance to market another product, the company is poised for more revenue.

Recent News:

RIVER EDGE, NJ — (Marketwired) — 12/27/16 — Nephros, Inc. (OTCQB: NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its HydraGuard™ 10″ UltraFilter. Continue Reading

Uptick encourages investors to do their own due diligence in determining investment strategies that work for them. Uptick’s opinion is based on individual company and market factors. Invest at your own risk.

Source: Uptick Newswire

Related Post